{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:54:06Z","timestamp":1761486846314},"reference-count":21,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2002,7,24]],"date-time":"2002-07-24T00:00:00Z","timestamp":1027468800000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2002,7]]},"abstract":"<jats:p> <jats:bold>BACKGROUND<\/jats:bold>: An HIV\u20101 and HCV NAT blood screening assay (Procleix HIV\u20101\/HCV, Gen\u2010Probe, Inc.) simultaneously detecting HIV\u20101 and HCV RNA) has been implemented. Donor plasma samples reactive in the Procleix HIV\u20101\/HCV assay are tested with the HIV\u20101 and HCV discriminatory assays to resolve whether HIV\u20101 RNA, HCV RNA, or both are present.<\/jats:p><jats:p> <jats:bold>STUDY DESIGN AND METHODS<\/jats:bold>: To determine the specificity of the Procleix HIV\u20101\/HCV assay, data were analyzed for samples from 192,288 donations, tested in 16\u2010member pools. To determine sensitivity, data were analyzed for 2014 commercial samples known to contain HIV\u20101, HCV, or both, as well as 10 HIV\u20101 and 10 HCV commercial seroconversion panels.<\/jats:p><jats:p> <jats:bold>RESULTS<\/jats:bold>: The specificity of the Procleix HIV\u20101\/HCV assay was 99.7 percent. The HIV\u20101 and HCV discriminatory assays showed similar specificity. The sensitivity of the Procleix HIV\u20101\/ HCV assay was 99.9, 99.6, and 100 percent, respectively, for samples containing HIV\u20101, HCV, or both. The Procleix discriminatory assays were comparably sensitive. The Procleix discriminatory assays detected all tested samples of known HIV\u20101 subtype or HCV genotype. Procleix HIV\u20101\/HCV testing of seroconversion panels showed that the median times to a positive reaction for HIV\u20101 and HCV were reduced by 3 and 25 days, respectively, compared to serologic tests.<\/jats:p><jats:p> <jats:bold>CONCLUSION<\/jats:bold>: These studies support the use of the Procleix HIV\u20101\/HCV assay for routine blood donor screening.<\/jats:p>","DOI":"10.1046\/j.1537-2995.2002.00130.x","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T17:46:19Z","timestamp":1031247979000},"page":"876-885","source":"Crossref","is-referenced-by-count":26,"title":["Clinical specificity and sensitivity of a blood screening assay for detection of HIV\u20101 and HCV\u2003RNA"],"prefix":"10.1111","volume":"42","author":[{"given":"Janet","family":"Vargo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Knott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songbai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chyang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherrol","family":"McDonough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Giachetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Caglioti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Gammon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Brooks","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Stramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Mimms","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,7,24]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"Committee for Proprietary Medicinal Products (CPMP). The Introduction of nucleic acid amplification technology (NAT) for the detection of hepatitis C virus RNA in plasma pools (CPMP\/BWP\/390\/97). London: The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit; 1998."},{"key":"e_1_2_6_3_2","first-page":"4S","article-title":"for the NAT\/Retrovirus Epidemiology Donor Study Group. Comparison of preliminary observed yield of HCV and HIV minipool (MP) nucleic acid testing (NAT) with predictions from the incidence\/window period (INC\/WP) model (Abstract).","volume":"40","author":"Kleinman S","year":"2000","journal-title":"Transfusion"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00066982-200005010-00007"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40020143.x"},{"key":"e_1_2_6_6_2","unstructured":"Giachetti C Linnen J Kolk DP et al. Highly sensitive multiplex assay for detection of HIV\u20101 and HCV RNA. J Clin Microbiol submitted for publication."},{"key":"e_1_2_6_7_2","first-page":"164","article-title":"High throughput assay for the simultaneous or separate detection of human immunodeficiency virus (HIV) and hepatitis type C virus (HCV).","volume":"25","author":"McDonough SH","year":"1998","journal-title":"Infusion Ther Transfus Med"},{"key":"e_1_2_6_8_2","unstructured":"O'Brien TR George JR Epstein JS. Testing for antibodies to human immunodeficiency virus type 2 in the United States. Morbidity and Mortality Weekly Report 1992;41:1\u20109."},{"key":"e_1_2_6_9_2","unstructured":"Roche Diagnostics. Package insert COBAS AMPLICOR HIV\u20101 Monitor test. Version 1.5. Basel Switzerland: Roche Diagnostics; 1999."},{"key":"e_1_2_6_10_2","unstructured":"National Genetic Institute (NGI Culver City CA) personal communication."},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-0934(02)00012-5"},{"key":"e_1_2_6_12_2","unstructured":"Stramer SL et al. Application of nucleic acid testing to blood borne pathogens and emerging technologies OBRR\/CBER\/FDA workshop Dec. 4 2001. Washington."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1006\/biol.1999.0223"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)06318-1"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3148.2001.00300-2.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.8.2937-2945.2001"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606273342601"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00077-6"},{"key":"e_1_2_6_19_2","first-page":"72S","article-title":"Dynamics of HCV viremia and seroconversion in transfusion\u2010acquired HCV infections (abstract).","volume":"38","author":"Busch MP","year":"1998","journal-title":"Transfusion"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/beha.2000.0104"},{"key":"e_1_2_6_21_2","first-page":"25","article-title":"Dynamics of HCV viremia during early HCV infection: implications for minipool (MP) vs individual donation (ID) nucleic acid amplification testing (NAT) (abstract).","volume":"40","author":"Busch MP","year":"2000","journal-title":"Transfusion"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.5.1761-1766.2002"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1537-2995.2002.00130.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1537-2995.2002.00130.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1537-2995.2002.00130.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1537-2995.2002.00130.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T19:58:35Z","timestamp":1694375915000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1537-2995.2002.00130.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["10.1046\/j.1537-2995.2002.00130.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1537-2995.2002.00130.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7]]}}}